Inhibitory mechanisms of celastrol on human liver cytochrome P450 1A2, 2C19, 2D6, 2E1 and 3A4

被引:33
作者
Jin, Chunhuan [1 ]
He, Xin [1 ,2 ]
Zhang, Fangliang [1 ]
He, Lina [1 ]
Chen, Junxiu [1 ]
Wang, Lili [1 ,2 ]
An, Lijun [1 ]
Fan, Yaowen [1 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Sch Chinese Mat Med, Tianjin 300193, Peoples R China
[2] Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
CYP; herb-drug interaction (HDI); inhibition; in vitro; IN-VITRO; ENZYMES; MICROSOMES; OXIDATION; DRUGS;
D O I
10.3109/00498254.2014.1003113
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The present study was conducted to examine the possibility of herb-drug interaction by celastrol, which is a main compound isolated from Tripterygium wilfordii Hook F. using human liver microsomes with cocktail methods. Focused on its inhibitory manner on the metabolism of model probe substrates of five cytochrome P450 isoenzymes (CYP1A2, CYP2C19, CYP2D6, CYP2E1 and CYP3A4) in vitro which are important with the metabolism of different xenobiotics. 2. The results showed that celastrol inhibited the five types of human cytochrome P450 isoforms, with the IC50 values of 2.65 mu M (CYP3A4), 5.99 mu M (CYP2C19), 6.27 mu M (CYP2D6), 7.66 mu M (CYP1A2) and 9.38 mu M (CYP2E1), respectively. The data indicated that celastrol acted in different manners as an inhibitor of human cytochrome P450 isoforms, which showed that celastrol not only un-competitively inhibited the CYP1A2 and 2E1 activities, but also competitively inhibited the CYP2C19 and 2D6 activities with K-i values of 1.41, 2.29, 5.27 and 4.21 mM, respectively. Celastrol was also a mixed-type inhibitor of CYP3A4, with K-i and K-is values of 2.02 and 5.49 mu M, respectively. 3. Celastrol has the potential to inhibit cytochrome P450 activities and may cause the herbdrug interactions. Therefore, the use of celastrol and its preparations with conventional medicines should thus be taken in to account.
引用
收藏
页码:571 / 577
页数:7
相关论文
共 27 条
[1]   Effects of diabetes on rabbit kidney and lung CYP2E1 and CYP2B4 expression and drug metabolism and potentiation of carcinogenic activity of N-nitrosodimethylamine in kidney and lung [J].
Arinc, Emel ;
Arslan, Sevki ;
Bozcaarmutlu, Azra ;
Adali, Orhan .
FOOD AND CHEMICAL TOXICOLOGY, 2007, 45 (01) :107-118
[2]   Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells [J].
Boridy, S. ;
Le, P. U. ;
Petrecca, K. ;
Maysinger, D. .
CELL DEATH & DISEASE, 2014, 5 :e1216-e1216
[3]   Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine [J].
Carrillo, JA ;
Christensen, M ;
Ramos, SI ;
Alm, C ;
Dahl, ML ;
Benítez, J ;
Bertilsson, L .
THERAPEUTIC DRUG MONITORING, 2000, 22 (04) :409-417
[4]   Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse [J].
Dinger, Julia ;
Meyer, Markus R. ;
Maurer, Hans H. .
TOXICOLOGY LETTERS, 2014, 230 (01) :28-35
[5]   Assessment of CYP1A2 activity in clinical practice: Why, how, and when? [J].
Faber, MS ;
Jetter, A ;
Fuhr, U .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2005, 97 (03) :125-134
[6]   Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson's disease [J].
Faust, Katharina ;
Gehrke, Stephan ;
Yang, Yufeng ;
Yang, Lichuan ;
Beal, M. Flint ;
Lu, Bingwei .
BMC NEUROSCIENCE, 2009, 10 :109
[7]   Cytochrome P450 enzymes mechanism based inhibitors: Common sub-structures and reactivity [J].
Fontana, E ;
Dansette, PM ;
Poli, SM .
CURRENT DRUG METABOLISM, 2005, 6 (05) :413-454
[8]   Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia [J].
Fukumoto, Kyoko ;
Kobayashi, Takashi ;
Tachibana, Kanako ;
Kat, Ryuji ;
Tanaka, Kazuhiko ;
Komamura, Kazuo ;
Kamakura, Shiro ;
Kitakaze, Masafurni ;
Ueno, Kazuyuki .
DRUG METABOLISM AND PHARMACOKINETICS, 2006, 21 (06) :501-505
[9]   Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].
Goldstein, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355
[10]   The 2006 Bernard B. Brodie Award Lecture - CYP2E1 [J].
Gonzalez, Frank J. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (01) :1-8